Imidazoline receptor (subtypes I1 and I2) (Imidazoline receptor (I1, I2))

The imidazoline receptors are a family of pharmacologically defined binding sites classified primarily as I1 and I2 subtypes, with unclear molecular identity, that recognize imidazoline-containing and related ligands. The I1-imidazoline receptor, likely a membrane-associated protein in the brainstem and peripheral tissues, plays a major role in lowering blood pressure by inhibiting sympathetic outflow and modulating catecholamine synthesis. I1 receptor activation is exploited by antihypertensive drugs such as moxonidine and rilmenidine, and may involve neurocytokine-like signaling and phospholipid metabolism. The I2-imidazoline receptor is mainly located on the mitochondrial outer membrane, thought to represent an allosteric site on monoamine oxidase, has a less clearly defined signaling function, and is implicated in neuroprotection, pain modulation, and mood regulation; I2 ligands have advanced to clinical trials for chronic pain and major depressive disorder. Due to their overlap with alpha-2 adrenoceptors, many drugs display mixed activity, and the lack of a cloned gene or unique protein marker complicates further research and therapeutic targeting.

Other names

I1-imidazoline receptorI1 receptorI2-imidazoline receptorI2 receptorImidazoline binding site I1Imidazoline binding site I2

I1 agonists lower blood pressure by decreasing central sympathetic tone. I2 agonists (possible allosteric modulation of monoamine oxidase, with neuroprotective and analgesic effects). Some drugs act via both imidazoline and alpha-2 adrenergic receptors.